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MicroRNA-31 (miR-31) is overexpressed in esophageal squamous
cell carcinoma (ESCC), a deadly disease associated with dietary Zn
deficiency and inflammation. In a Zn deficiency-promoted rat ESCC
model with miR-31 up-regulation, cancer-associated inflammation,
and a high ESCC burden following N-nitrosomethylbenzylamine
(NMBA) exposure, systemic antimiR-31 delivery reduced ESCC in-
cidence from 85 to 45% (P = 0.038) and miR-31 gene knockout
abrogated development of ESCC (P = 1 × 10−6). Transcriptomics,
genome sequencing, and metabolomics analyses in these Zn-deficient
rats revealed the molecular basis of ESCC abrogation by miR-31
knockout. Our identification of EGLN3, a known negative regulator
of nuclear factor κB (NF-κB), as a direct target of miR-31 establishes
a functional link between oncomiR-31, tumor suppressor target
EGLN3, and up-regulated NF-κB–controlled inflammation signaling.
Interaction among oncogenic miR-31, EGLN3 down-regulation, and
inflammation was also documented in human ESCCs. miR-31 de-
letion resulted in suppression of miR-31–associated EGLN3/NF-κB–
controlled inflammatory pathways. ESCC-free, Zn-deficient miR-31−/−
rat esophagus displayed no genome instability and limited meta-
bolic activity changes vs. the pronounced mutational burden and
ESCC-associated metabolic changes of Zn-deficient wild-type rats.
These results provide conclusive evidence that miR-31 expression
is necessary for ESCC development.
zinc deficiency | esophageal squamous cell carcinoma | esophageal cancer
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Despite recent advances in surgery, radiation, and chemother-apy, esophageal squamous cell carcinoma (ESCC) remains a
deadly disease with only 10% of patients surviving for 5 y (1).
Thus, a critical need exists to elucidate further the molecular
pathogenesis of ESCC that could in turn provide the development
of new therapeutic strategies.
Alcohol and tobacco use, nutritional deficiencies, and exposure to
environmental carcinogens, including N-nitrosomethylbenzylamine
(NMBA) (2), are among the known risk factors for ESCC. In
many populations (3–5), and in individuals with chronic alcohol
consumption (6), dietary zinc (Zn) deficiency is implicated in the
etiology of ESCC. Abnet et al. (5) showed that high vs. low tissue
Zn concentration is associated with a reduced risk of developing
ESCC, providing evidence in humans of an association between
Zn deficiency and ESCC. We have developed a Zn-deficient
(ZD) rat esophageal cancer model that reproduces the Zn-
deficiency and inflammation features of human ESCC (7) and
is highly sensitive to esophageal tumorigenesis induced by
NMBA (8). Rats on a ZD diet for 5 wk develop hyperplastic
esophagi with a distinct gene signature that includes up-regulation
of the proinflammation mediators S100a8/a9 (9) and over-
expression of the oncogenic microRNA-31 (miR-31) (10). Pro-
longed Zn deficiency leads to an expanded cancer-associated
inflammatory program and an oncogenic miRNA signature, with
miR-31 as the top up-regulated species that fuels ESCC devel-
opment (8, 11).
miRNAs are commonly dysregulated in human cancers and
miR-31 is among the most frequently altered of the miRNAs in
cancers (12). Depending on tumor type, miR-31 can exhibit
oncogenic or tumor suppressive roles. miR-31 is overexpressed
and oncogenic in colorectal cancer (13) and squamous cell carci-
nomas of the esophagus (14), tongue (15), head and neck (16), and
skin (17), but the mechanisms whereby miR-31 up-regulation
promotes development of these cancers remain unclear.
Locked nucleic acid (LNA)-modified RNA oligonucleotides
exhibit high biostability, low toxicity, and adequate biodistribution
in vivo (18). For example, in vivo LNA-antimiR-122 was shown to
mediate effective inhibition of liver-expressed miR-122 function
in mice and nonhuman primates (19). Using LNA-antimiR-31, we
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previously demonstrated in a ZD rat esophageal preneoplasia
model overexpressing miR-31 that silencing miR-31 in vivo inhibits
the development of esophageal preneoplasia by repressing the miR-
31–associated STK40-NF-κB (nuclear factor κB)–based inflamma-
tion signaling (10). Since the end point was the preneoplastic in-
flammatory esophageal phenotype, we questioned whether miR-31
silencing could suppress progression to ESCC in NMBA-treated
Zn-deficient rats.
Using a Zn deficiency-promoted rat ESCC model with
prominent miR-31 overexpression (11) and a cancer-associated
inflammatory gene signature (8), we investigated the effects of
LNA-mediated antimiR-31 delivery, or constitutive knockout of
miR-31, on NMBA-induced ESCC development in ZD rats. We
found that in vivo LNA-antimiR-31 delivery moderately suppressed
ESCC development, whereas genetic miR-31 knockout completely
protected ZD:miR-31−/− rats from ESCC development. In parallel,
we examined the molecular consequences of miR-31 silencing in
ESCC suppression by analyzing gene expression and metabolomics
profiles. Because genome instability is an important “hallmark” of
cancer development, we were also interested, during this “omics”
study, to include whole-genome sequencing (WGS) of esophageal
tissue samples from NMBA-treated rat cohorts: ESCC-bearing
Zn-deficient wild-type (WT) rats, Zn-sufficient (ZS) WT rats
with undetectable tumors, and tumor-free ZD:miR-31−/− rats.
Results
AntimiR-31 Delivery Inhibits ESCC Development in Zn-Deficient Rats.
To determine if in vivo antimiR-31 delivery silences miR-31 and
suppresses the development of ESCC, we performed a 20-wk
anticancer study in the ZD rat ESCC model with miR-31 up-
regulation (11) and a cancer-associated inflammatory gene signa-
ture (8). We used an LNA-mediated rno-miR-31a-5p inhibitor
probe (designated antimiR) to inhibit esophageal miR-31 expres-
sion and an LNA-negative-control-A probe (designated CTRL-A)
as a control oligo (10). As depicted in Fig. 1A (see treatment de-
tails in Materials and Methods), 4-wk-old rats were randomized
Fig. 1. Systemic delivery of locked nucleic acid-mediated antimiR-31 suppresses esophageal carcinogenesis. (A) Study design. (B) Body weights, serum Zn
levels, and esophageal miR-31 levels (qPCR) (rat snoRNA as normalizer; Tukey-HSD post hoc unpaired t test for multiple comparisons; error bars represent SD; n = 8
rats per group). (C) Macroscopic view of whole esophagus. Representative photos of ZD:CTRL (R13, R14) and ZD:CTRL-A/20-wk (R15, R16) with multiple large/sessile
esophageal tumors vs. ZD:antimiR/20-wk (R1 to R4) esophagi with small/isolated tumors (arrowheads). (D) Tumor multiplicity (number of tumors per esophagus;
error bars represent mean ± SD) (two-tailed Welch t test; n = 8 to 20 rats per cohort); large tumor (size > 2 mm) and ESCC incidence (%) (two-tailed Fisher’s exact
test; n = 8 to 20 rats per cohort). (E) Histopathologic changes (arrowheads highlight the most relevant histological findings) in ZD esophagus after antimiR-31
treatment. Representative photos of ZD:antimiR/20-wk vs. ZD:CTRL esophagus showing H&E staining, IHC staining for KRT14 (brown, 3,3′-diaminobenzidine
tetrahydrochloride; DAB), and PCNA (red, 3-amino-9-ethylcarbazole substrate chromogen; AEC) and ISH localization of miR-31 (blue, BCIP/NBT; counterstain,
nuclear fast red) (n = 8 rats per cohort).
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into four Zn-deficient cohorts (ZD:antimiR/20-wk, ZD:antimiR/
5-wk, ZD:CTRL-A, ZD:CTRL) and one Zn-sufficient group
(ZS:CTRL). ZD:antimiR/20-wk and ZD:CTRL-A/20-wk rats re-
ceived 30 i.v. doses of antimiR or CTRL-A over the 20-wk study,
ZD:antimiR/5-wk rats received 10 doses over the first 5 wk, and
ZD:CTRL and ZS:CTRL rats were untreated. At week 5, the
animals received intragastric NMBA doses once a week for 4 wk
and were killed 15 wk post first NMBA dose or 48 h after the
final oligo delivery. At tumor end point, ZD cohorts displayed
similar body weights, indicating the LNA-mediated oligo treat-
ment was well-tolerated (Fig. 1B). Serum Zn level was similar in
all four ZD cohorts (∼55 μg/100 mL) but significantly lower than
in ZS rats (P < 0.001) (Fig. 1B). As expected (10), ZD:CTRL
and ZD:CTRL-A rats were comparable in all parameters mea-
sured (Fig. 1 B–D). Thus, ZD:CTRL rats served as a control in
the analysis.
As in previous studies (11), qPCR analysis showed that dietary
Zn deficiency prominently up-regulated miR-31 expression in
the esophagus (ZD:CTRL vs. ZS:CTRL, P < 0.001) (Fig. 1B).
AntimiR treatment (20 wk) resulted in ∼90% reduction of
esophageal miR-31 levels in ZD:antimiR/20-wk rats vs. ZD:CTRL
(P < 0.001) (Fig. 1B). At the cellular level, miR-31 analysis by in situ
hybridization (ISH) in formalin-fixed, paraffin-embedded (FFPE)
esophageal tissues revealed marked reduction in intensity/extent of
miR-31 signal in ZD:antimiR/20-wk vs. ZD:CTRL cohort (Fig. 1E;
n = 10 rats per cohort), validating the qPCR data. Consistent with
the long-lasting effect of antimiR (19), ZD:antimiR/5-wk esopha-
gus, assessed 15 wk after antimiR dosing, showed an ∼70% de-
crease in miR-31 levels vs. ZD:CTRL tissues (P < 0.001) (Fig. 1B).
Independent of antimiR treatment, ZD cohorts had 100%
overall esophageal tumor incidence vs. ZS:CTRL rats with 25%
incidence. Macroscopically (Fig. 1C; n = 8 to 20 rats per group),
ZD:antimiR/20-wk esophagus (rats R1 to R4) typically had smaller
and fewer tumors vs. ZD:CTRL (R13, R14) or ZD:CTRL-A/20-wk
(R15, R16) esophagus showing multiple large/sessile tumors. Thus,
antimiR delivery (20 wk) led to a large decrease in tumor multi-
plicity (5.7 vs. 14, P = 4 × 10−5), in large tumor incidence (45 vs.
85%, P = 0.038; size >2 mm), and in ESCC incidence (45 vs. 85%,
P = 0.038) (Fig. 1D), as assessed by histological examination of
hematoxylin & eosin (H&E)-stained and KRT14-immunostained
sections (Fig. 1E). Thus, despite sustained dietary ZD, prolonged
antimiR-31 delivery (20 wk) significantly reduces ESCC incidence by
40%. In contrast, a short-term antimiR delivery (5 wk) led to a
modest reduction in tumor multiplicity vs. ZD:CTRL rats (9.9 vs. 14,
P = 0.002) (Fig. 1D).
miR-31 Knockout Abrogates ESCC Development in ZD:miR-31−/− Rats.
To understand the molecular interaction between miR-31 and
dietary Zn deficiency in ESCC development, we generated a
constitutive miR-31 knockout (KO) rat (Materials and Methods)
with deletion of a 466-bp DNA fragment containing miR-31 in
one allele by CRISPR/Cas9 technology (20, 21) in the same
Sprague–Dawley rat strain as our previous Zn deficiency-associated
esophageal tumor studies. miR-31–null rats were generated by
breeding and selection of rats carrying two KO alleles. Because off-
target effects are a concern of gene silencing technology, 10 po-
tential off-targets for the upstream single-guide (sg)RNA and 10
sites for the downstream sgRNA were searched. Cas9-mediated
mutations were not detected among those 20 potential off-target
sites. The production of homozygous miR-31 KO rat pups in
normal sex ratios showed that miR-31 deletion is well-tolerated
in the rat and miR-31−/− rats exhibit no discernible abnormal
phenotypes.
First, we assessed the effect of dietary Zn deficiency alone on
esophageal cell proliferation and inflammation in miR-31−/− rats
(SI Appendix, Fig. S1). Zn deficiency (20 wk) induced pronounced
miR-31 up-regulation and a highly proliferative and inflammatory
esophageal phenotype in WT ZD:miR-31+/+ vs. ZS:miR-31+/+
rats, with overexpression of the inflammation markers COX-2 and
S100A8/S100A9 and the transcription factor NF-κB p65. In con-
trast, deficient ZD:miR-31−/− rats displayed a noninflammatory
and nonproliferative esophageal phenotype similar to the ZS:miR-
31−/− counterpart (SI Appendix, Fig. S1).
Next, we investigated the consequences of miR-31 genetic
knockout on ESCC development by performing a 20-wk esopha-
geal tumor bioassay by NMBA, as for in vivo antimiR-31 delivery.
As shown in Fig. 2A, 4-wk-old miR-31 KO and WT littermates
were fed a ZD or ZS diet to form four cohorts: ZD:miR-31−/−,
ZD:miR-31+/+, ZS:miR-31−/−, and ZS:miR-31+/+. At week 5, the
rats received intragastric NMBA doses, once a week for 4 wk. The
study was concluded at 15 wk post first NMBA dose. At tumor end
point, regardless of genotype, Zn-deficient cohorts had compara-
ble body weights and lower serum Zn levels vs. the Zn-sufficient
cohort (P < 1 × 10−4) (Fig. 2B). qPCR analysis showed that
esophageal miR-31 expression was barely detectable in KO co-
horts (0.12 ± 0.17 and 0.06 ± 0.06 in ZD:miR-31−/− and ZS:miR-
31−/−). Conversely, WT cohorts showed the expected prominent
miR-31 expression in ZD:miR-31+/+ vs. ZS:miR-31+/+ rats (164 ±
63 vs. 4.8 ± 1.6) (Fig. 1B). At the cellular level, in situ miR-31
analysis in FFPE esophageal tissues revealed no miR-31 signal in
ZD:miR-31−/− or ZS:miR-31−/− (Fig. 3D) esophagus compared
with abundant/intense miR-31 signal in esophageal mucosa and
tumor in ZD:miR-31+/+ (Fig. 2E) (Fig. 3D, ZD:CTRL). There-
fore, the qPCR and ISH data confirm that miR-31 is knocked out
in miR-31−/− rats.
Macroscopically (Fig. 2C), we found small/isolated esophageal
tumors (∼0.5 mm) in a few ZD:miR-31−/− rats compared with
the omnipresent large/sessile tumors (>2 mm) in ZD:miR-
31+/+ esophagus. Thus, ZD:miR-31−/− rats had significantly
lower esophageal tumor incidence/multiplicity than ZD:miR-
31+/+ rats (tumor incidence, 55 vs. 100%, P = 0.007; multiplicity,
1.6 ± 1.7 vs. 11.6 ± 5.1, P = 7 × 10−7) (Fig. 2D); 0% (0/20) of
ZD:miR-31−/− rats developed ESCC compared with 75% (15/20)
of ZD:miR-31+/+ rats (P = 0.00003). While ZD:miR-31−/− esopha-
geal epithelia were mostly thin (Fig. 2F; H&E), with an occasional
hyperplastic hyperkeratotic focus featuring basal cell proliferation
(Fig. 2F; proliferating cell nuclear antigen [PCNA]), ESCC-bearing
ZD:miR-31+/+ esophagus regularly showed uncontrolled cellular
proliferation and inflammatory cell infiltrates in the stroma (Fig. 2
E and F). The data showed that Zn deficiency is unable to promote
ESCC in ZD:miR-31−/− rats, providing conclusive genetic evidence
that miR-31 is necessary for ESCC development.
Expression of Cancer-Related Inflammation Genes in miR-31–Silenced
Esophagus. To identify genes critical in ESCC suppression after
miR-31 knockdown or knockout, we performed comparative
transcriptomics profiles of esophageal mucosa-derived RNA from
six cohorts, ZD:CTRL, ZS:CTRL, ZD:antimiR/5-wk, ZD:antimiR/
20-wk, ZD:miR-31−/−, and ZS:miR-31−/−, using the Affymetrix Rat
230 2.0 Genome GeneChip (n = 4 to 6 rats per cohort). Hierarchical
clustering of messenger (m)RNA profiles using a cutoff of P < 0.05
and logFC (fold change) of 1 revealed that the ZD esophagi had
distinct gene expression patterns compared with ZS:CTRL esopha-
gus (Fig. 4 A and B). ZD:CTRL esophagus showed an inflammatory
signature with prominent up-regulation of six cancer-related in-
flammation genes: S100a8, Ptgs2, S100a9, Ccl2, Cxcl14, andCxcl1 (SI
Appendix, Table S1 and Dataset S1). None of the six up-regulated
inflammation genes was differentially expressed in ZD:antimiR/20-
wk vs. ZS:CTRL (SI Appendix, Table S1 and Dataset S2), ZD:miR-
31−/− vs. ZS:CTRL esophagus (SI Appendix, Table S1 and Dataset
S4), or ZD:miR-31−/− vs. ZS:miR-31−/− esophagus (Dataset S3),
although three inflammation genes (S100a8, Cxcl14, and Cxcl1)
were moderately up-regulated in ZD:antimiR/5-wk esophagus
(SI Appendix, Table S1). Additionally, the expression profile of
ZD:miR-31−/− esophagus revealed prominent down-regulation of
Ptgs2, S100a9, and S100a8 compared with ZD:CTRL esophagus
Fong et al. PNAS | March 17, 2020 | vol. 117 | no. 11 | 6077
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(ranging from logFC −3.8 to −2.2) (Dataset S5). These gene ex-
pression profiles showed that the Zn deficiency-induced up-
regulation of key inflammation genes was reversed by in vivo
miR-31 silencing or by genetic miR-31 knockout. qPCR data (Fig.
4C) confirmed that these three genes that were markedly up-
regulated by Zn deficiency were strikingly restored to normal
ZS:CTRL levels in ZD:antimiR/20-wk and ZD:miR-31−/− esoph-
agus. At the protein level, immunohistochemistry (IHC) anal-
ysis (Fig. 4D) showed strong/abundant cytoplasmic staining for
all three inflammation markers COX2, S100A8, and S100A9
and their transcription factor NF-κB p65 (22, 23) in cancerous
ZD:CTRL vs. ZS:CTRL esophagus. Expression of the same
inflammation markers and NF-κB p65, a key mediator of in-
flammation (24), was reduced in ZD:antimiR/20-wk esophagus
and became weak/diffuse in ZD:miR-31− /−, as well as in
ZS:miR-31− /− esophagus, both featuring a noninflammatory
and nonproliferative esophageal phenotype.
Egln3 and Mboat2 Are Tumor Suppressor Targets of miR-31 in ESCC.
We previously identified STK40 as a direct miR-31 target in
esophageal preneoplasia (10). To identify physiological miR-31
targets in ESCC, we performed genome-wide mRNA expression
profiling and analyzed genes with derepressed transcript levels in
response to in vivo antimiR-31 delivery (20 wk). Among the 86
most derepressed mRNAs in ZD:antimiR/20-wk vs. ZD:CTRL
esophagus (Fig. 4A, first and third heatmaps), the human/rat
TargetScan tool predicts that miR-31-5p potentially targets
MBOAT2, CTNND2, FRK, and EGLN3 (Fig. 3A). To deter-
mine if miR-31-5p is a negative regulator of MBOAT2, CTNND2,
and EGLN3 genes, we performed luciferase assays. As shown in
Fig. 3B, HEK-293FT cells were cotransfected with a vector
expressing either the WT or the mutated versions of the 3′ un-
translated regions (UTRs) of theMBOAT2, CTNND2, and EGLN3
genes, and either premiR-31-5p or scrambled negative control 1.
Luciferase reporter assays (Fig. 3B) indicated direct interac-
tions between miR-31-5p and both MBOAT2 (P < 0.0005)
and EGLN3 (P < 0.001), confirming that they are direct miR-
31 targets.
The comparative transcriptomics data revealed that genetic
miR-31 knockout led to a marked up-regulation of all three miR-
31 tumor suppressor targets Egln3 (logFC 1.04, P = 0.00059),
Mboat2 (logFC 1.18, P = 1.51E-5), as well as Stk40 (logFC 1.38,
P = 1. 51E-11) in ZD:miR-31−/− vs. ZD:CTRL esophagus
(Dataset S5). This result was borne out in our CDF (cumulative
distribution function) plot of Egln3, Stk40, and Mboat2 in
ZD:CTRL (WT), ZS:CTRL (WT), and ZD:miR-31−/− rat esoph-
agus showing that the expression of Egln3, Stk40, and Mboat2 was
down-regulated in miR-31–overexpressing ZD:CTRL esophagus vs.
the ZS:CTRL counterpart but was up-regulated in ZD:miR-31−/−
esophagus compared with ZD:CTRL esophagus (SI Appendix, Fig. S2).
Fig. 2. Genetic miR-31 knockout completely prevents ESCC development. (A) Study design. (B) Body weights, serum Zn levels, and qPCR analysis of esophageal
miR-31 levels (snoRNA as normalizer; error bars represent mean ± SD; Welch’s t test; n = 12 rats per cohort; ns, not significant). (C) Macroscopic view of whole
esophagus. Representative photos of ZD:miR-31−/− vs. ZD:miR-31+/+ esophagus (arrowheads indicate esophageal tumors). (D) Overall tumor incidence and ESCC
incidence (%) (Fisher’s exact test) and tumor multiplicity (number of tumors per esophagus; error bars represent mean ± SD) (Welch t test). Statistical tests were
two-sided (n = 20 rats per ZD cohort). (E) miR-31 localization in esophagus. Representative photos of ZD:miR-31−/− vs. ZD:miR-31+/+ tissues (miR-31 ISH signal; blue,
BCIP/NBT) (n = 20 rats per cohort). Arrowheads indicate esophageal epithelium. (F) Histopathologic changes inmiR-31−/− rat esophagus (arrowheads emphasize the
difference in epithelia response to dietary ZD in miR-31−/− vs. miR-31+/+ esophagus and the similarity in the epithelia response in the ZS:miR-31−/− vs. ZS:miR-31+/+
esophagus). Representative photos of ZD:miR-31−/− vs. ZD:miR-31+/+ and ZS:miR-31−/− vs. ZS:miR-31+/+ esophagus showing histology (H&E), IHC staining for KRT14
(brown, DAB), and PCNA (red, AEC) (n = 20 rats per cohort). (G) Prevalence of somatic mutations in esophageal epithelia in ZD:CTRL (WT), ZS:CTRL (WT), and
ZD:miR-31−/− rats with divergent esophageal tumor outcome. ZD:CTRL (R13) and ZD:CTRL (R14) esophagus, respectively, had high and low tumor burden; ZS:CTRL
had no observable tumors, and nonproliferative ZD:miR-31−/− esophagus was tumor-free.
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Additionally, qPCR analysis confirmed that Egln3 (P = 0.001)
and Mboat2 (P = 0.0008) levels were significantly higher in
ZD:miR-31−/− vs. ZD:CTRL esophagus (Fig. 3C), validating the
microarray result. Using ISH for miR-31 detection and IHC for
protein expression analysis (Fig. 3D), ZD:miR-31−/− esophagus
had moderate cytoplasmic immunostaining of EGLN3, MBOAT2,
and STK40 protein in basal and suprabasal cells, whereas
ZD:CTRL esophagus with intense/abundant miR-31 signal dis-
played weak/absent expression of the same three proteins com-
pared with ZD:miR-31−/− and ZS:CTRL esophagus, validating
EGLN3 and MBOAT2 as miR-31 direct targets at both the
mRNA and protein levels.
EGLN3 (also known as PHD3) belongs to the Caenorhabditis
elegans gene egl-9 (EGLN) family of prolyl hydroxylases. EGLN3
is down-regulated in colorectal cancer cells (25) and is a negative
regulator of the NF-κB–controlled pathway (25, 26). The role of
MBOAT2 (a member of the membrane-bound O-acyltransferase
family) in pathological conditions is largely unknown. Because
EGLN3 is a known negative regulator of NF-κB, a key mediator
of inflammation, we focused our study on EGLN3.
Effects of Genetic miR-31 Knockout on the EGLN3-NF-κB–Based
Inflammatory Pathway. To determine if a functional connection
occurs among oncomiR-31, EGLN3, STK40, and NF-κB–controlled
signaling in ESCC, we examined the FFPE esophageal tissue
findings on in situ detection of miR-31 and IHC analysis of its
target EGLN3/STK40 protein (Fig. 3D) along with IHC analy-
sis of the NF-κB–controlled COX-2/S100A8/S100A9 inflamma-
tion pathway (Fig. 4D). In ESCC-bearing ZD:CTRL esophagus,
miR-31 overexpression was associated with down-regulation of
EGLN3 and STK40 proteins (Fig. 3D) and accompanying up-
regulation of the NF-κB–controlled COX-2/S100A8/S100A9
inflammation pathway (Fig. 4D). Strikingly, genetic knockout of
miR-31 in ZD:miR-31−/− esophagus up-regulated EGLN3 and
STK40 protein expression (Fig. 3D) and abolished this NF-κB
p65-controlled inflammation network (Fig. 4D), giving rise to a
nonproliferative and tumor-free esophageal phenotype. Similarly,
in vivo antimiR-31 delivery derepressed miR-31 tumor suppressor
targets (SI Appendix, Fig. S3) and attenuated the same NF-κB–
controlled inflammatory pathway (Fig. 4D), decreasing ESCC
development (Fig. 1 C–E). These in vivo data establish the func-
tional connections between oncomiR-31, EGLN3, and STK40 and
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Fig. 3. miR-31-5p targets EGLN3 and MBOAT2 expression. (A) Venn diagram showing the intersection between 86 genes that were the most derepressed
after antimiR-31 treatment and predicted miR-31 target genes from TargetScan human/rat software. (B) Transfection experiments were performed in HEK-
293FT cells using constructs for 3 predicted miR-31 targets, MBOAT2, EGLN3, and CTNND2. Renilla luciferase activity was normalized to firefly luciferase
activity. The normalized luciferase activity in 293FT cells transfected with empty psiCHECK2 vector and scrambled negative control 1 (premiR-N.C.1) and
relative luciferase activities of 293FT cells transfected with all other combinations of psiCHECK2 constructs and premiR oligos are shown. Experiments were
repeated thrice in duplicate and data are presented as mean ± SD. Luciferase reporter assays indicate direct interactions between miR-31-5p and MBOAT2
(P < 0.005) and between miR-31-5p and EGLN3 (P < 0.001), two-tailed Student’s t test. (C) mRNA expression of Egln3 and Mboat2 in esophageal mucosa-
derived RNA from ZD:CTRL, ZS:CTRL, and ZD:miR-31−/− rats (Psmb6 as normalizer; error bars represent mean ± SD; n = 7 to 11 rats). P values represent the
significant difference between each individual group and ZD:CTRL rats; two-tailed, one-way ANOVA and Tukey post hoc t tests. (D) Protein expression of miR-
31 targets EGLN3, MBOAT2, and STK40 (arrowheads emphasize the abundant/intense miR-31 overexpression in ZD:CTRL vs. ZS:CTRL esophagus). Repre-
sentative photos of ZD:CTRL, ZS:CTRL, ZD:miR-31−/−, and ZS:miR-31−/− esophagus showing miR-31 ISH signal (blue, NBT/BCIP) (EGLN3, MBOAT2, and STK40
protein expression; brown, DAB; n = 10 rats per cohort). (E) Connection between miR-31 expression, protein expression of EGLN3 and STK40, and in-
flammation markers in human ESCC tissue. Representative photos of human ESCC tissue (FFPE sections): Case 1, case 2, and normal esophageal mucosa in case
2 showing miR-31 ISH signal (blue, NBT/BCIP) (EGLN3, STK40, COX-2, S100A8, S100A9, and NF-κB p65 protein expression; brown, DAB; n = 10 patient cases).
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NF-κB p65-controlled signaling in ESCC, providing a mechanism
for miR-31 promotion of ESCC.
miR-31 Overexpression, EGLN3 Down-Regulation, and Inflammation in
Human ESCC Tissue. To examine a similar mechanistic link between
miR-31 and inflammation in human ESCC, we retrieved archived
human FFPE ESCC tissues (n = 10 patient cases) and performed
in situ miR-31 analysis by ISH, EGLN3 and STK40 protein ex-
pression, and the NF-κB–controlled COX-2/S100A8/S100A9 in-
flammation pathway by immunohistochemistry. Overexpression of
the proinflammation markers S100A8 (9), S1009 (27), and COX-2
(28) has been reported in human ESCC. Consistent with our
previous data (10, 11), miR-31 ISH signal was abundant and strong
in all 10 cases of ESCC tumor tissue (Fig. 3E). This miR-31
overexpression was accompanied by weak to absent expression
of its tumor suppressor EGLN3 and STK40 protein (Fig. 3E).
Because EGLN3 (29) and STK40 (30) are negative regulators of
NF-κB–mediated transcription, their down-regulation unleashed a
robust inflammatory response, with strong expression of the in-
flammation mediator NF-κB p65 and its target proinflammation
markers COX-2, S100A8, and S100A9 (Fig. 3E), establishing a
mechanistic connection between oncogenic miR-31, its tumor
suppressor targets EGLN3 and STK40, and inflammation in
human ESCC.
ZD:CTRL Rat Esophagus Exhibits a Tumor-Associated Metabolome.
Cancer cells rewire cellular metabolism to adapt to increased
demands for energy and cellular biosynthesis to sustain tumor
growth (31). Changes in metabolite levels define the purpose of
cellular regulation by genes and proteins (32). Metabolites are
also key actors in biological networks by feedback inhibition or
activation of enzymes. Additionally, miRNAs have emerged as
key regulators of cellular metabolism in normal and pathological
conditions (33). To determine if the diverse esophageal tumor
Fig. 4. In vivo miR-31 silencing abolishes overexpression of cancer-related inflammation genes in esophagus. (A) Heatmaps (logFC 1, P < 0.05) showing
distinct expression profiles of ZD:CTRL vs. ZS:CTRL, ZD:antimiR/5-wk vs. ZS:CTRL, and ZD:antimiR/20-wk vs. ZS:CTRL. (B) Heatmaps (logFC 1, P < 0.05) showing
distinct expression profiles of ZD:miR-31−/− vs. ZS:CTRL and ZD:miR-31−/− vs. ZS:miR-31−/−. (C) mRNA expression (qPCR) of S100a8, Ptgs2, and S100a9 (top up-
regulated inflammation genes; SI Appendix, Table S1) in ZD:CTRL, ZS:CTRL, ZD:antimiR/20-wk, and ZD:miR-31−/− esophagus (error bars represent mean ± SD;
n = 7 to 11 rats per cohort; P values represent the significant difference between each individual group and the ZD:CTRL group; two-tailed, one-way ANOVA
and Tukey post hoc t tests). (D) Protein expression (IHC) of COX-2, S100A8, S100A9, and NF-κB p65 (arrowheads emphasize the overexpression of the four
inflammation markers in ZD:CTRL esophagus; brown, DAB; n = 10 rats per cohort). Representative photos of ZD:CTRL, ZS:CTRL, ZD:antimiR/20-wk, ZD:miR-
31−/−, and ZS:miR-31−/− esophagus.
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outcomes in ZD:CTRL (WT) vs. ZD:miR-31−/− are reflected
in their metabolomes, we performed nontargeted metabolomics
profiling on esophageal mucosa in five cohorts (ZD:CTRL,
ZD:antimiR/20-wk, ZS:CTRL, ZD:miR-31−/−, and ZS:miR-31−/−)
using gas chromatography time-of-flight mass spectrometry
(GC-TOF MS), a method previously used in metabolomics
analyses in ovarian cancer (34).
Most metabolomics analyses in ESCC had been performed on
serum/plasma from patients, with limited ESCC tissue analyses
(35, 36). Based on P value < 0.05, our differential analysis
identified 69 significantly altered metabolites (38 up- and 31
down-regulated) in the high ESCC-burden ZD:CTRL esophagus
vs. ESCC-free ZS:CTRL. To obtain a biochemical overview of
classic univariate statistical differences between ZD:CTRL and
ZS:CTRL esophagi (SI Appendix, Table S2), we constructed a
metabolomics network (37) among the structurally identified
metabolites using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) databases (38) and PubChem compound ID number
(CID) identifiers (39). This network analysis (Fig. 5A) showed that
of the 38 up-regulated metabolites in ZD:CTRL esophagus, about
1/3 (32%) were associated with metabolic alteration in amino acid
(AA) metabolism. Differences in AA levels have been reported
in many human cancers, including ESCC (35, 36, 40). Six AAs
(lysine, histidine, proline, serine, tyrosine, glycine) are similarly
up-regulated in human ESCC (36). The remaining up-regulated
metabolites are involved in anabolic/biosynthetic pathways, including
Fig. 5. Metabolomics profiling by GC-TOF MS reveals divergent esophageal metabolic phenotypes in ZD:CTRL (WT) and ZD:miR-31−/− rats. (A) ESCC-bearing
ZD:CTRL vs. ZS:CTRL esophagus showing 38 up- and 31 down-regulated metabolites. (B) Tumor-free ZD:miR-31−/− vs. ZS:miR-31−/− esophagus showing limited
metabolic changes (eight up- and three down-regulated metabolites). Each node denotes an identified metabolite (red, up-regulated; blue, down-regulated;
yellow, insignificant change; Mann–Whitney U test, P < 0.05). Metabolite size reflects median fold change. Metabolites are connected based on biochemical
relationships (red lines) or structural similarity (blue lines). Molecules not directly participating in biochemical transformations but sharing structural prop-
erties were connected at a threshold of Tanimoto similarity coefficient ≥0.7 (n = 9 rats per group).
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purine/pyrimidine metabolism (adenosine-5-monophosphage,
thymine). In particular, putrescine (an intermediate in polyamine
biosynthesis) was up-regulated 6.4-fold (P = 0.0001) in ZD:CTRL
esophagus. Polyamines are indispensable for cell growth and ma-
lignant transformation (41).
Of the 31 down-regulated metabolites in ZD:CTRL esophagi
(Fig. 5A and SI Appendix, Table S2), 16 (52%) were carbohydrates,
including the glycolytic intermediates (glucose-6-phosphate,
phosphoenolpyruvate). Increased glycolysis that produces glyco-
lytic intermediates to furnish subsidiary pathways for sustaining
tumor growth is a characteristic of cancer cell metabolism.
For insights into biological mechanisms underlying the effect
of dietary ZD on ESCC development, we performed analysis of
chemical similarity enrichments (ChemRICH) (42) that detects
sets of metabolites and uses Kolmogorov–Smirnov statistics to
test the significance of differential regulation. ChemRICH analysis
showed that a total of 13 metabolite clusters differed significantly
(FDR < 0.05) in ZD:CTRL vs. ZS:CTRL esophagus (SI Appendix,
Fig. S4A and Table S5). Three clusters were found at decreased
levels (hexoses, hexosephosphates, purine nucleosides), three
clusters at increased levels (AAs, dicarboxylic acids, purine nu-
cleotides), and seven clusters contained up-regulated and down-
regulated compounds. Thus, ChemRICH showed that levels of
glycolytic intermediates were decreased and anabolic/biosynthetic
compounds increased, pointing to a classic cancer cell remodeling
of energy and nucleoside metabolism.
Few studies have investigated whether metabolite biomarkers
can be used to predict the efficacy of cancer treatment (43). Our
analysis of ZD:antimiR/20-wk vs. ZS:CTRL esophagus yielded
95 significantly altered metabolites (SI Appendix, Table S3).
Thirty up- and 28 down-regulated metabolites were common to
ZD:antimiR/20-wk vs. ZD:CTRL esophagus (SI Appendix, Fig.
S4C). Because polyamine biosynthesis is altered in human ESCC
(35), the result that the level of putrescine was reduced by 48%
with a P value approaching significance (P = 0.0625) (SI Ap-
pendix, Fig. S3D) suggests that putrescine could be a metabolite
biomarker in ESCC treatment.
ZD:miR-31−/− Rat Esophageal Metabolome Shows Limited Perturbation.
Finally, we determined the influence of genetic miR-31 knock-
out on the esophageal metabolome in ZD:miR-31−/− rats that
exhibited an ESCC-free esophageal phenotype. In sharp con-
trast to the ZD:CTRL metabolome, metabolomics analyses of
ZD:miR-31−/− vs. ZS:miR-31−/− rat esophagus yielded only 11
significantly altered metabolites (Fig. 5B and SI Appendix, Table
S4) and two significantly altered metabolite clusters (SI Appen-
dix, Fig. S3B and Table S6).
ZD:miR-31−/− Rat Esophagus Exhibits a Stable Genome. Cancer is a
genetic disease and the genome instability observed, a “hallmark
of cancer,” occurs in virtually all cancers, though there has been
less focus on genome instability in rodent tumors. Our nutrige-
nomics profiling of the rat ZD esophageal models for following
hyperplasia and neoplasia development has shown that the
miRNA and metabolomics data for these rat lesions mirror the
miRNA and metabolome alterations in human ESCC, prompting
us to determine, by WGS, if there were differential genomic al-
terations in the NMBA-induced cancerous tissues of rat models.
After quality checks and filtering of the WGS data and analysis
of sequences for altered genes in four rat tissue DNAs, we ob-
served very few genetic alterations in the ZS:CTRL vs. ZD:CTRL
(rats R13 and R14, Fig. 1C). In WT genomes, the number of
variants per Mb of genome was computed (Fig. 2G). The
ZD:miR-31−/− mucosa, without evident tumors, showed only two
in-frame deletions and a single nucleotide insertion in a different
gene on a different chromosome, all with possible moderate effect
on protein products. The ZS:CTRL rat (WT) tissue without evi-
dent tumors showed only four genome alterations at three loci,
each with a possible moderate effect on protein products (SI Ap-
pendix, Table S7). The ZD:CTRL (R14) rat with low tumor bur-
den and ZD:CTRL (R13) rat with high tumor burden showed 7
and 14 mostly in-frame deletions/insertions, with moderate
effects on specific genes (SI Appendix, Table S7). These se-
quences, with relatively high mutational effect, showed significant
mutations in genes that might have affected tumor development,
nine genes in the R14 sample and 22 genes in the ZD:CTRL R13
mucosal DNA. A gene ontology analysis was performed for the
gene alterations with “HIGH” and “MODERATE” effects to find
most enriched gene processes (SI Appendix, Tables S8 and S9). The
most commonly affected processes in both HIGH and MODER-
ATE effect mutations were biological regulation, metabolic process,
and response to stimulus.
Discussion
In a Zn deficiency-promoted rat ESCC model, we used omics
tools to examine the molecular consequences of miR-31 silenc-
ing by antimiR-31 delivery and by genetic miR-31 knockout. This
model that mimics features of human ESCC, including dietary
ZD, miR-31 overexpression, and inflammation, exhibits a high
ESCC burden, prominent miR-31 up-regulation, and a cancer-
associated inflammatory signature (5, 7, 8, 10, 11, 14). We find
that prolonged antimiR-31 delivery knocks down esophageal
miR-31 levels in ZD:antimiR/20-wk vs. ZD:CTRL rats and reduces
ESCC incidence by 40%, counteracting the ESCC-promoting ef-
fects of Zn deficiency. This result extends our previous antimiR-31
delivery study in esophageal preneoplasia (10) and affirms the
oncogenic role of miR-31 in human ESCC (14). Remarkably,
with genetic miR-31 knockout, Zn deficiency per se does not
create a precancerous esophageal phenotype in ZD:miR-31−/−
rats as it does in WT ZD:miR-31+/+ rats. At tumor end point,
nonmalignant small/isolated esophageal tumors were found in
a few ZD:miR-31−/− rats in contrast to large/sessile tumors in
most ZD:miR-31+/+ esophagi. Strikingly, none of the 20
ZD:miR-31−/− rats developed ESCC compared with 15 of the
20 ZD:miR-31+/+ rats. While ZD:miR-31−/− esophageal epithelia
were thin with occasional hyperplastic foci, ESCC-bearing ZD:miR-
31+/+ esophagi showed unrestrained cellular proliferation and in-
flammatory cell infiltrates in the stroma. These data show that Zn
deficiency does not promote ESCC in ZD:miR-31−/− rats, providing
conclusive genetic evidence that miR-31 expression is required for
ESCC development.
Our comparative transcriptomics data showed that the high
ESCC-burden ZD:CTRL esophagus displayed a Zn deficiency-
induced inflammation gene signature with up-regulation of six
human ESCC-associated inflammation genes (8), including
S100A8 (9), S100A9 (27), and COX-2 (28). In contrast, expres-
sion of proinflammatory genes is absent in ESCC-free ZD:miR-
31−/− esophagus or in ZD:antimiR/20-wk esophagus, with a 40%
reduction in ESCC incidence. Because inflammation, a hallmark
of cancer (31), is central to the pathogenesis of ESCC (7, 44), the
data suggest that suppression of inflammation is a mechanism by
which genetic miR-31 knockout abrogates ESCC development.
We also identified and validated EGLN3, a known colorectal
cancer tumor suppressor and negative regulator of the NF-κB–
controlled pathway, as a miR-31 direct target. Loss of EGLN3
allows tumors to overcome hypoxic growth inhibition and sustain
proliferation through EGFR (45), though its regulation in cancer
remains not well-understood. Our in situ miR-31 analysis by ISH
and EGLN3/STK40-NF-κB–controlled COX-2/S100A8/S100A9
protein expression analysis revealed that genetic miR-31 deletion
leads to suppression of the EGLN3/STK40-NF-κB–controlled
inflammation pathway, opposite of results with ESCC-bearing
ZD:CTRL esophagus and of human ESCC tissue, in which miR-
31 overexpression suppresses EGLN3, setting free the NF-κB
p65-controlled inflammation signal. These data establish a connec-
tion between oncomiR-31 and EGLN3/STK40-NF-κB–controlled
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signaling in ESCC and establish the mechanism by which miR-31
promotes human ESCC. We predict this could be a mechanism
for oncogenic miR-31 in inflammation-associated human can-
cers such as colorectal cancer, where miR-31 overexpression
(13), EGLN3 down-regulation (25), and NF-κB activation (46)
have been reported.
Because Egln3 is a direct target of miR-31 and miR-31 KO rats
do not develop Zn deficiency-associated ESCC even after expo-
sure to NMBA, a limitation of the study is whether overexpressing
the EGLN3-negative regulator of NF-κB will eliminate ESCC
development as does the miR-31 knockout, assuming that the NF-
κB inflammatory signal pathway is the main inducer of ESCC in
this rat model. Studies are in progress to specifically address
this issue.
Metabolomics analysis showed that the ESCC-bearing ZD:CTRL
esophagus has a highly dysregulated metabolome, with 69 signifi-
cantly altered metabolites. In particular, ∼32% of the up-regulated
metabolites are implicated in active amino acid biosynthesis, a
common feature of human ESCC (35, 36, 40). Phosphoenolpy-
ruvate, the top down-regulated species in ZD:CTRL vs. ZS:CTRL
esophagus (−5.83-fold, P = 0.010), is a metabolic checkpoint of
antitumor T cell responses (47). Uridine, involved in the regulation
of carbohydrate and pyrimidine nucleotide synthesis, is decreased
3.58-fold (P = 0.0008) in ZD:CTRL esophagus. Uridine levels
were also down-regulated in human ESCC (35). In combination,
these data establish that dietary Zn deficiency causes a tumor-
associated esophageal metabolome profile resembling that of
human ESCC.
Remarkably, despite sustained Zn deficiency, genetic miR-31
knockout produced an esophageal metabolome with limited
metabolic changes in ZD:miR-31−/− esophagus compared with
its ZS:miR-31−/− counterpart. This nontumor metabolome is
reflected by the ESCC-free esophageal phenotype in ZD:miR-
31−/− animals.
The results of the genome sequence analysis of the rat esoph-
ageal tissues at tumor end point did not uncover large numbers of
mutations but found alterations with high or moderate effect on
the proteins mutated in the ZD:CTRL WT rats, while there were
virtually no mutations in the ZD:miR-31−/− rat or the ZS:CTRL
WT rat. This genomic instability could be due to exposure of the
rat GI tract to the nitrosamine carcinogen NMBA, and the accu-
mulated mutations would likely show the mutational signature
recently described for the environmental carcinogen NMBA (48).
It is interesting that without expression of miR-31, an NMBA
mutational signature appears to be suppressed, suggesting that the
inflammation signal pathway might contribute to production of the
carcinogen-induced mutations. But we emphasize that the sup-
pression of epithelial proliferation and associated cellular signal
pathways are also necessary for NMBA induction of mutations.
The most interesting finding from the WGS study was that the
miR-31 KO rat, even with ZD and carcinogen treatment, did not
show genome alterations, confirming that the miR-31 signaling
pathway is required for development of ESCC in this rat model, as
in the counterpart human cancers.
In summary, in a Zn deficiency-promoted rat ESCC model,
with miR-31 overexpression and inflammation pathway up-reg-
ulation, we reveal that in vivo antimiR-31 delivery suppresses,
and miR-31 genetic knockout abrogates, ESCC development.
Our identification of EGLN3, a known negative regulator of NF-
κB, as a direct target of miR-31 establishes a functional link
between the oncomiR-31 tumor suppressor gene target, EGLN3,
and the NF-κB p65-controlled inflammation signaling, which in
turn promotes ESCC in both human and rat tissue. Additionally,
our study shows that counteracting the ESCC-promoting effect
of dietary Zn-deficiency genetic miR-31 knockout leads to the
eliminating of entire biological processes, including the miR-
31-EGLN3/STK40-NF-κB–controlled inflammatory pathway,
esophageal cancer metabolism, and an unstable genome. Thus, our
findings provide insight into the mechanisms whereby Zn deficiency
or miR-31 promotes ESCC. Our data also provide a mechanistic
rationale for development of therapeutic strategies to target miR-31
in ESCC and for Zn replenishment in ESCC prevention.
Materials and Methods
Rats, Diets, and Carcinogen. Weanling male Sprague–Dawley rats (55 ± 5 g)
were from Taconic Laboratory. Custom-formulated ZD and ZS diets (Harlan
Teklad) were identical except for the amount of Zn, which was 3 to 4 ppm
for the ZD and ∼60 ppm for the ZS diet. NMBA was from the Midwest Re-
search Institute. Animal protocols were approved by the Thomas Jefferson
University Animal Care and Use Committee.
Locked Nucleic Acid AntimiR-31 Inhibitor. An in vivo grade of phospho-
rothioated miRCURY LNA-enhanced rno-miR-31a-5p inhibitor probe (SI Ap-
pendix, Table S10) was dissolved in sterile phosphate-buffered saline (PBS)
and stored at −80 °C.
Generation of an miR-31−/− Rat Model. Sage Labs was commissioned to custom
generate a constitutive miR-31−/− rat model on the Sprague–Dawley genetic
background by CRISPR/Cas9 technology (20, 21).
Anticancer Studies.
AntimiR-31 delivery in the ZD rat ESCC model. Four-week-old male Sprague–
Dawley rats were divided into four ZD groups and a ZS group. ZD rats were
fed ad libitum and ZS rats were pair fed to deficient animals to match their
decreased food consumption (10). The animals received PBS-formulated
LNA-antimiR or LNA-CTRL-A oligonucleotides or were untreated, forming
five cohorts: ZD:antimiR/5-wk (n = 12), ZD:antimiR/20-wk (n = 11), ZD:CTRL-
A/20-wk (n = 8), ZD:CTRL (untreated, n = 20), and ZS:CTRL (untreated, n = 8).
Over a period of the first 5 wk (10), ZD:antimiR/5-wk, ZD:antimiR/20-wk, and
ZD:CTRL-A/20-wk cohorts received via tail vein a loading dose of antimiR or
CTRL-A (20 mg·kg−1), followed by nine maintenance doses (6 mg·kg−1, twice
weekly). Starting at week 5 (11), the animals were given four intragastric
doses of NMBA (2 mg·kg−1, once per week for 4 wk). During and following
NMBA administration (15 wk), ZD:antimiR/20-wk and ZD:CTRL-A/20-wk rats
received 20 additional antimiR or CTRL-A doses (6 mg·kg−1, twice per week
for 5 wk and then once per wk for the remaining 10 wk). The animals were
weighed weekly and killed 48 h after the final dose of antimiR or CTRL-A or
15 wk after the first NMBA dose. Blood was obtained from the retroorbital
venous plexus for serum preparation. Whole esophagus was excised, longi-
tudinally slit open, and photographed. Tumors >0.5 mm in diameter were
mapped. Esophagi were cut into two equal portions. Esophageal epithelium
was isolated, snap-frozen in liquid nitrogen, and stored at −80 °C. The
remaining portion was fixed in 10% buffered formalin.
Esophageal tumorigenesis in miR-31−/− rats. Four-week-old male miR-31−/− and
miR-31+/+ littermates were randomly divided into a ZD or ZS dietary group.
The animals were divided into NMBA-untreated groups (10 rats per group)
and NMBA-treated groups (20 rats per group), using the same NMBA-
induced tumor assay as described above.
RNA Isolation. Total RNA was extracted from the pulverized esophageal
mucosal samples using an RNA extraction kit (Norgen Biotek; 25700). The
integrity of the RNA was analyzed by an Agilent 2100 Bioanalyzer and RNA
integrity number was ≥8 for all samples.
TaqMan miRNA Assay. Reverse transcription (Applied Biosystems) of miRNAs
was performed. qRT-PCR was performed using TaqMan miRNA assays, mmu-
miR-31 (ID 000185), and endogenous controls small nucleolar (sno)RNA (ID
001718) and U87 (ID 001712). As an overall quality control, threshold cycle
values above 35 were excluded from analysis.
ISH. ISH was performed (10) using miRCURY LNA microRNA detection probes
rno-miR-31 and negative control (rno-miR-31 with mismatches at two posi-
tions) double DIG-labeled at the 5′ and 3′ ends (Exiqon). miRNA was local-
ized by incubation with 4-nitro-blue tetrazolium (NBT) and 5-bromo-4-
chloro-3′-indolylphosphate (BCIP) (Roche). Nuclear fast red (Vector Labs) was
used as a counterstain.
qRT-PCR. cDNAwas reverse-transcribed using the High-Capacity cDNAArchive
Kit (Applied Biosystems). qPCR was performed using the ΔΔCt method of
qPCR data analysis and single-tube TaqMan gene expression assays with
S100A8 (Rn00587579_g1), S100A9 (Rn00585879_m1), Ptgs2 (Rn01483828_m1),
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Egln3 (Rn00571341_m1), and Mboat2 (Rn01472966_m1) and normalizers
Psmb6 (Rn02377140_g1) and Oaz1 (Rn01408148_g1).
Gene Expression Profiling. Expression profiling of esophageal epithelia was
performed at the Ohio State University Comprehensive Cancer Center Ge-
nomics Facility using the Affymetrix Rat Genome 230 2.0 GeneChip (10).
Expression Data Analysis. The processing of raw files was performed using the
Expression Console (Affymetrix). The normalization was performed using
robust multiarray normalization implemented in the Expression Console and
Rat_230.CDF. Differentially expressed genes were identified using the R
package (limma). The heatmaps were created using custom R scripts and the
function heatmap.2 of gplots.
DNA Constructs. For psiCHECK2-MBOAT2-WT, a 1,494-bp-long fragment of
the MBOAT2 3′ UTR (corresponding to positions 1733 to 3226 of National
Center for Biotechnology Information [NCBI] reference sequence NM_138799.4)
containing two predicted target sites for miR-31-5p was cloned downstream of
the Renilla luciferase gene in the psiCHECK2 vector (Promega). For psiCHECK2-
CTNND2-WT, an 864-bp-long fragment of the CTNND2 3′ UTR (corresponding to
positions 4298 to 5161 of NCBI reference sequence NM_001332.4) was cloned in
the psiCHECK2 vector. For psiCHECK2-EGLN3-WT, a 368-bp-long fragment of
the EGLN3 3′ UTR (corresponding to positions 1047 to 1414 of NCBI reference
sequence NM_022073.3) was cloned in the psiCHECK2 vector. The predicted
miR-31-5p site in EGLN3 is located at position 159 to 166 of the EGLN3 3′ UTR.
Two predicted miR-31-5p sites in MBOAT2 are located at positions 376 to 382
and 1268 to 1274 of the MBOAT2 3′ UTR. Substitutions in predicted miR-31-5p
binding sites to produce mutated sites unable to bind miR-31-5p were in-
troduced by using the QuikChange II XL Site-Directed Mutagenesis Kit (Stra-
tagene) following the manufacturer’s instructions (see oligonucleotides used in
SI Appendix, Table S10).
Cell Cultures and Luciferase Assay. HEK-293FT cells were cultured in RPMI
medium 1640 (Sigma-Aldrich) supplemented with 10% FBS, 25 μg/mL gen-
tamicin, and 1% glutamine (Sigma-Aldrich) at 37 °C in a 5% CO2 incubator.
Transfections were carried out with Lipofectamine 2000 following the
standard protocol (Life Technologies). HEK-293FT cells were seeded in 12-
well plates the day before transfection. Cells were cotransfected with 250 ng
of various psiCHECK2 vector constructs and 100 nM premiR-31-5p or
scrambled negative control 1 (Thermo Fisher Scientific). Twenty-four hours
after transfection, firefly and Renilla luciferase activities were measured
using the Dual-Luciferase Report Assay (Promega).
IHC. IHC was performed (10) using primary antibodies for PCNA (clone PC-10;
Ab-1; Thermo Scientific), KRT14 (NCL-LL002; Novocastra), COX-2 (12282; Cell
Signaling), S100A8 (T-1032; BMA), S100A9 (NB110-89726; Novus Biologicals),
NF-κB p65 (ab7970; Abcam), STK40 (orb101780; Biorbyt), EGLN3 (orb443107;
Biorbyt), and MBOAT2 (orb185503; Biorbyt). Protein was localized by in-
cubation with the 3-amino-9-ethylcarbazole substrate chromogen (Dako) or
3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich).
Metabolomics Profiling by GC-TOF MS. Frozen rat esophageal mucosa were
shipped to the NIHWest Coast Metabolomics Center (University of California,
Davis). Esophageal tissue was extracted, derivatized, and processed as
described (34). Primary metabolite analysis was performed by GC-TOF MS
using cold injection/automatic liner exchange (CIS-ALEX GC-TOF MS; Leco
Pegasus IV) (49).
ChemRICH. Chemical set enrichment statistical analysis was performed on
metabolomics data as described (42, 49).
Metabolome Network Visualization. Using KEGG and PubChem CIDs, a bio-
chemical and chemical similarity network (37, 49) was calculated for all
measured metabolites.
Genomic DNA Isolation. High-quality nondegraded genomic DNA was
extracted from esophageal epithelia isolated using the DNeasy Blood &
Tissue Kit (Qiagen).
WGS.DNA library preparation, library quality control, and nonhumanWGS to
yield ∼30× coverage were performed on the Illumina HiSeq X at HudsonAlpha
Genomic Services Laboratory.
WGS Analysis. WGS reads were mapped against the Rnor6.0 (Rattus norve-
gicus) reference using BWA (50). The read postprocessing analysis was per-
formed after the alignment using Picard (http://broadinstitute.github.io/
picard/). The read duplicate marking was performed using MarkDuplicate.
GATK was used for the step of calling variants. Single-nucleotide variants
were selected considering QD (QualByDepth) <2.0, FS (FisherStrand) >60,
MQ (Mapping Quality) <40, MQRankSum <−12.5, and ReadPosRankSum <−8.0.
Only the indels with QD <2.0, FS >200, and ReadPosRankSum <20 were selected
for downstream analysis. The resulting VCF files were annotated with the variant
effect predictor (VEP) (https://www.biorxiv.org/content/10.1101/501817v2) using
the following options: –species Rattus_norvegicus–offline–pick–ccds–hgvs–sym-
bol–protein. VEP allows the annotation of the variants considering the dif-
ferent effects on the proteins. Only the variants with MODERATE or HIGH
effect were selected for downstream analysis. Additional filters were applied
to maintain only the most deleterious variants at the level of the sequence
(e.g., frameshift_variants, splice_acceptor_variant, etc.).
Microscopy. IHC and ISH analyses were performed by light microscopy
(Olympus BX51 microscope), and photographs were taken with a Spot RT3
camera and Spot software version 5.2.
Zn Measurement. Serum Zn content was determined using Atomic Absorption
Spectrometer Analyst 400 (PerkinElmer).
Statistical Analysis. ANOVA and Tukey post hoc t tests (or Kruskal–Wallis and
pairwise Wilcoxon rank-sum tests for groups with nonnormally distributed
data) were used to determine the differences among the groups. Tumor and
ESCC incidence data among the groups were evaluated using the χ2 test.
Individual differences in incidence data were then assessed using Fisher’s
exact test. The Mann–Whitney U test was used to detect significant com-
pounds in metabolomics. All statistical tests were two-sided and considered
significant at P < 0.05. Statistical analysis was performed by R (http://www.R-
project.org).
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